• Ascendis Pharma A/S ASND.OQ reported a quarterly adjusted loss of 64 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of €-1.54. The mean expectation of fourteen analysts for the quarter was for a loss of 96 cents per share. Wall Street expected results to range from €-1.78 to 23 cents per share.

• Revenue rose 26.3% to €173.92 million from a year ago; analysts expected €119.71 million.

• Ascendis Pharma A/S's reported EPS for the quarter was a loss of 64 cents​.

• The company reported a quarterly loss of €38.47 million.

• Ascendis Pharma A/S shares had fallen by 13.2% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 33.9% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Ascendis Pharma A/S is $196.00

This summary was machine generated from LSEG data February 13 at 02:55 a.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)